Coherus BioSciences (CHRS) announced final data from its Phase 2 open label clinical trial evaluating casdozokitug, a selective and potent ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

This significant downturn reflects a staggering 1-year change, with the company's stock value eroding by -84.83%. Investors have watched with concern as Omega, known for its innovative approaches in ...

Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.